Clinical Trials Sponsored by Eisai Inc.

Total 35624 results

Eisai Inc.

Terminated

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Advanced Solid Tumors

United States
Eisai Inc.

Completed

A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)

Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC

United States
Eisai Inc.

Completed

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

Alzheimer's Disease

United States
Eisai Inc.

Completed

A Study to Determine the Signs and Symptoms That Impact Daily Life of Participants With Irregular Sleep-Wake Rhythm Disorder

Irregular Sleep Wake Rhythm Disorder

United States
Eisai Inc.

Completed

Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)

Insomnia Disorder

United States, Canada, Finland, Germany, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Romania, Spain
Eisai Inc.

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia

Elderly | Chronic Insomnia | Adults

United States
Eisai Inc.

Completed

Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder

Insomnia Disorder

United States
Eisai Inc.

Terminated

A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Thyroid Carcinoma, Anaplastic

Italy, United States, France, Australia, United Kingdom
Eisai Inc.

Completed

BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management

Obesity

United States
Eisai Inc.

Completed

Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

Pharmacokinetics in Obese Adolescents

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment

Renal Impairment

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State

Obesity

United States
Eisai Inc.

Completed

Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung

KIF5B-RET-Positive Adenocarcinoma of the Lung

United States, Hong Kong, Japan, Taiwan, Singapore
Eisai Inc.

Completed

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

Healthy Volunteers

United States
Eisai Inc.

Completed

Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers

Healthy Volunteers

United States
Eisai Inc.

Approved for marketing

Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil

Thyroid Cancer

Brazil
Eisai Inc.

Completed

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

Healthy Participants

United States
Eisai Inc.

Terminated

Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT

Parkinson's Disease

United States
Eisai Inc.

Completed

Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

Idiopathic Thrombocytopenic Purpura

United States
Eisai Inc.

Completed

Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

Thrombocytopenia Associated With Liver Disease

United States, China, Spain, Argentina, Belgium, Israel, Mexico, Romania, Japan, Brazil, Russian Federation, Germany, Italy, Czechia, Canada, Australia, France
Eisai Inc.

Completed

A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors

Advanced Colorectal Cancer

United States, Canada
Eisai Inc.

Completed

A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures

Seizure Disorder Generalized Tonic Clonic
Eisai Inc.

Completed

ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis

Severe Sepsis

United States, France, Poland, United Kingdom, Germany, Hong Kong, Taiwan, Spain, Switzerland, Argentina, Belgium, Israel, South Africa, Japan, Canada, Netherlands, Korea, Republic of, Australia, Chile, Brazil, Austria, Italy, Czechia, Portug...
Eisai Inc.

Completed

A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects

Early Alzheimer's Disease

United States
Eisai Inc.

Completed

E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

Soft Tissue Sarcoma

France, Germany, Belgium, Denmark, Poland
Eisai Inc.

Completed

Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy

Epilepsy | Primary Generalized Tonic-Clonic Seizures | Partial-Onset Seizures
Eisai Inc.

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult Subjects

Healthy Participants

United States
Eisai Inc.

Completed

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

Chronic Plaque Psoriasis

United States
Eisai Inc.

Completed

A PK/PD Study of Fospropofol Disodium Compared With Propofol Injectable Emulsion

Anesthesia

United States
Eisai Inc.

Completed

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease

Coronary Artery Disease

United States
Eisai Inc.

Completed

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

Cancer: Solid Tumors

Japan
Eisai Inc.

Approved for marketing

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Differentiated Thyroid Cancer

United States
Eisai Inc.

Completed

Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures

Epilepsy

Greece, Italy, Spain, Sweden, Korea, Republic of, Germany, Australia, France, Switzerland, Slovakia, Poland, Taiwan, Hungary, Serbia, India, United Kingdom, Denmark, Russian Federation, South Africa, Montenegro
Eisai Inc.

Completed

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

Chile, Canada, United States, Estonia, India, Hungary, Bulgaria, Croatia, Australia, Lithuania, Latvia, Argentina, France, Germany
Eisai Inc.

Completed

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

Metastatic Melanoma

United States
Eisai Inc.

Completed

4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures

Epilepsy

Belgium, France, United States, Czech Republic, Estonia, Latvia, Spain, United Kingdom, Lithuania, Germany, Australia, Finland, Netherlands, Sweden
Eisai Inc.

Completed

An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male Subjects

Healthy Subjects

United States
Eisai Inc.

Completed

A Study to Characterize Pharmacokinetics (PK) and Pharmacodynamics (PD) of LUSEDRA® Administered as Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable Emulsion

Monitored Anesthesia Care

United States
Eisai Inc.

Completed

A Study to Assess the Transfer of Fospropofol and Its Active Metabolite, Propofol, to Breast Milk Following Administration of LUSEDRA to Lactating Women Undergoing a Needed Procedure

Lactating Women

United States
Eisai Inc.

Completed

A Study to Determine the Effect of a High-Fat Meal on the Rate and Extent of E2006 Absorption in Healthy Subjects

Healthy Subjects

United States
Eisai Inc.

Completed

A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects

Healthy Volunteers

United States
Eisai Inc.

Terminated

A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Eisai Inc.

Completed

An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies

Solid Tumor Malignancies, Cancer

United States
Eisai Inc.

Completed

Efficacy and Safety Study of E2007 in Migraine Prophylaxis

Migraine Prophylaxis

United States
Eisai Inc.

Completed

A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

Parkinson's Disease

United States
Eisai Inc.

Approved for marketing

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Metastatic Breast Cancer

Canada, Belgium, France
Eisai Inc.

Completed

A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects

Renal Impairment | Disease Severity

United States
Eisai Inc.

Withdrawn

A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Acute Myelogenous Leukemia (AML)

India
Eisai Inc.

Completed

A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers

Healthy Volunteers

United States
Eisai Inc.

Withdrawn

To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures

Epilepsy, Partial

3

Subscribe